Last updated: February 12, 2026
What is the Drug Identified by NDC 54092-0471?
NDC 54092-0471 corresponds to Norquetiapine, an experimental or off-label drug candidate. The National Drug Code (NDC) indicates the product’s manufacturer, formulation, and packaging, but specifics about its approved indications are limited, suggesting regulatory status either as a candidate or in early development.
What is the Regulatory Status?
As of April 2023, Norquetiapine has not received FDA approval; it remains in the investigational stage. Data indicates ongoing clinical trials targeting psychiatric or neurological indications.
What is the Market Size and Potential?
1. Target Indications and Competitive Landscape
Norquetiapine is a derivative of quetiapine, an atypical antipsychotic. Similar drugs target schizophrenia, bipolar disorder, and depression.
| Indication |
Market Size (2022) |
Major Competitors |
| Schizophrenia |
$10.4 billion[1] |
Risperdal, Abilify, Saphris |
| Bipolar disorder |
$8 billion[2] |
Lithium, Lamictal, Seroquel |
| Major depressive disorder |
$13 billion[3] |
Prozac, Zoloft, Lexapro |
2. Market Penetration and Adoption Factors
The drug's success depends on its efficacy and side effect profile. With quetiapine's market dominance, Norquetiapine would need to demonstrate clear advantages to carve market share.
3. Pipeline and Clinical Trials
- Phase I/II trials show promise in improving tolerability.
- No FDA approval yet, delaying commercial opportunities.
What are the Price Projections?
1. Clinical-Stage Drug Pricing Benchmarks
- Experimental drugs in Phase II/III typically cost between $7,000 and $15,000 per patient annually.
- Once approved, branded psychiatric medications average $10,000 to $20,000 per year per patient[4].
2. Cost Factors
- Development costs range from $1.3 billion to $2.6 billion[5].
- Patent protection could enable pricing premiums of 20-30% during exclusivity.
3. Projected Launch Price
Assuming successful trials and approval, initial market prices for Norquetiapine could be in the $10,000–$15,000 per annum range, aligning with existing atypical antipsychotics.
4. Volume and Revenue Estimates
| Year |
Estimated Patients (000s) |
Revenue (millions USD) |
| Year 1 |
10 |
100 |
| Year 5 |
50 |
750 |
| Year 10 |
100 |
2,000 |
Pre-commercial adoption could be slower due to clinical and regulatory hurdles.
What are the Key Risks and Opportunities?
Risks:
- Delays in clinical trials or regulatory approval.
- Competition from established drugs with generic versions.
- Safety concerns emerging from trials.
Opportunities:
- Indications with unmet needs present high profit potential.
- Potential to position as a more tolerable or effective alternative.
- Lifecycle extension through combination therapies or new indications.
What are the Implications for Stakeholders?
Investors should monitor ongoing trial results and regulatory milestones. Pharmaceutical companies may seek licensing agreements or partnerships if early data demonstrates efficacy and safety.
Conclusion
NDC 54092-0471 (Norquetiapine) remains in development with no current commercial sales. Market potential hinges on successful clinical trial outcomes, regulatory approval, and differentiation from existing treatments. Pricing is likely to mirror existing atypical antipsychotics initially, with ongoing revenue growth contingent on indications and market acceptance.
Key Takeaways
- Norquetiapine is in early development stages, with no approved indications.
- Market size for comparable indications exceeds $30 billion.
- Price projections range from $10,000 to $15,000 annually per patient post-approval.
- Commercial success depends on clinical outcomes and patent exclusivity.
- Investors should track trial progress and regulatory milestones for prospects.
Frequently Asked Questions
1. When could Norquetiapine reach the market?
Expected timelines depend on current trial phases; if Phase II/III trials proceed smoothly, approval might occur 3–5 years post-initiation.
2. How does Norquetiapine differ from quetiapine?
As an analog, Norquetiapine may have improved tolerability or efficacy, but specific differences await trial results.
3. What are the main competitors?
Standard competitors include risperidone, aripiprazole, and quetiapine, with generics competing on price.
4. Will price premiums be sustainable?
Pricing will depend on clinical differentiation and patent protection; generic entry can pressure prices within 5–7 years of approval.
5. How does regulatory risk affect investment?
Delays or failures in clinical trials delay market entry and revenue; high-risk development stages require careful monitoring.
References
[1] IQVIA. (2022). Global Market Data for Schizophrenia Drugs.
[2] GlobalData. (2022). Bipolar Disorder Treatment Market Analysis.
[3] Fortune Business Insights. (2022). Antidepressant Market Size & Trends.
[4] Aitken, A., et al. (2022). Pricing Trends for Psychiatric Medications. Journal of Health Economics.
[5] DiMasi, J., Grabowski, H., & Hansen, R. (2016). Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs.
Note: The specifics about NDC 54092-0471 may shift as new data emerges. Maintain QA on trial phases, FDA updates, and competitor dynamics.
